British Journal of Haematology · 2005 · 34 citations · 36 references
Life SciencesCancer BiologyOncologyApoptosisCancer ImmunologyImmunopathologyApoptosis In CancerBcl-2 Family ProteinsGrowth Factor SignalingAntiapoptotic Protein RegulationAutocrine Growth LoopsAutocrine HormonesAutocrine LoopsAutocrine Signaling LoopsGrowth Factor-receptor InteractionsInsulin-like Growth Factor Receptor SignalingLymphocyte Apoptosis
Chronic lymphocytic leukaemia (CLL) is characterized by the accumulation of long-lived B lymphocytes blocked in G(0/1) by impaired apoptosis. As insulin-like growth factor-I (IGF-I) is known for its antiapoptotic effects in different cell types, we investigated whether IGF-I and its receptor (IGF-IR) participate in autocrine/paracrine loops affecting the survival of CLL cells. IGF-IR protein and mRNA was present in CLL cells in 44% and 59% of patients respectively. IGF-IR expression in CLL patients was positively correlated with the expression of the antiapoptotic protein Bcl-2 and was involved in CLL cell survival in vitro. Serum IGF-I was elevated in CLL patients, but growth hormone (GH) was normal. CLL cells expressed IGF-I mRNA and secreted the growth factor in vitro. Therefore, local production of IGF-I can account for the increased levels of serum IGF-I, independently of GH, and may be related to autocrine/paracrine control of lymphocyte survival acting at IGF-IR. This is the first demonstration of IGF-IR expression in a subgroup of CLL patients and of its antiapoptotic effects in vitro, highlighting the importance of this growth factor receptor as a possible therapeutic target in CLL.
36
Plasma Insulin-Like Growth Factor-I and Prostate Cancer Risk: A Prospective Study
June M. Chan, Meir J. Stampfer, Edward L. Giovannucci et al. · Science · 1998 · 2K citations
Medicine, Endocrinology, Urology +16
Circulating concentrations of insulin-like growth factor I and risk of breast cancer
Susan E. Hankinson, Walter C. Willett, Graham A. Colditz et al. · The Lancet · 1998 · 1.8K citations